Active Ingredient: BEVACIZUMAB
(Hérité de AVASTIN 25 mg/ml) According to a 2017 JAHA systematic review, Bevacizumab isn't known to cause QT prolongation despite it's known cardiotoxicity, but no sources pointing to a trial showing the absence of QT prolongation Caution is key
https://doi.org/10.1161/JAHA.117.007724